ReviewEpigenomics2025
The role of DNA methylation in directing treatment in medulloblastoma.
Review in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genome-wide DNA methylation analysis of pediatric medulloblastomas from a Brazilian cohort: an exploratory study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Advancing Medulloblastoma Treatment: Molecular Mechanisms, Drug Repurposing, and Precision Therapies.Molecular diagnosis & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medulloblastoma is the most common malignant childhood brain tumor. The disease exhibits significant clinical and molecular heterogeneity which leads to significant differences in outcome. Although survival rates have improved in recent years, outcome for patients with high-risk disease remains poor and survival is associated with significant treatment associated morbidity. Traditional risk stratification was established largely on the basis of clinical and histological factors, but these are not sufficient to capture the full biologic complexity of the disease. Recent advances have underscored the role of DNA methylation as a powerful epigenetic biomarker for precise subgroup stratification and prognostic classification of medulloblastoma into four primary molecular subtypes: WNT, SHH, Group 3, and Group 4. This review summarizes mechanisms of DNA methylation in cancer biology, methylation profiling analytical approaches, and their application in delineating medulloblastoma subtypes. Specific attention is placed on the clinical utility of methylation-based classifiers for guiding therapeutic decisions and clinical trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.